Fabre invests in French manufacturing
This article was originally published in Scrip
Executive Summary
Pierre Fabreplans to invest €70 million to expand its manufacturing capacity at its Soual site, near Castres in the Tarn region of France. The investment involves an additional 15,000m2 facility capable of producing an additional 60 million units of dermatology and cosmetic products destined mainly for overseas markets. Work is expected to begin a year from now and the facility is expected to become operational in 2011. The investment will add around 150 new employees to the company's workforce of 10,000.
You may also be interested in...
Cervarix link to UK girl's death "unlikely"
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Generic Topamax launched in European markets
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
NICE confirms limits on Alimta for lung cancer
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.